Loading...
FTH logo

Faeth Therapeutics, Inc.NasdaqCM:FTH Stock Report

Market Cap US$891.5m
Share Price
n/a
1Y283.3%
7D-7.9%
1D-1.8%
Portfolio Value
​
View

Faeth Therapeutics, Inc.

NasdaqCM:FTH Stock Report

Market Cap: US$891.5m

Faeth Therapeutics (FTH) Stock Overview

A clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. More details

FTH fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Analysts in good agreement that stock price will rise by 64.3%

Risk Analysis

Shareholders have been substantially diluted in the past year

Highly volatile share price over the past 3 months compared to the US market

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years


FTH Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW428,954 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
428,954 investors already sharing narratives
View all narratives

Faeth Therapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Faeth Therapeutics
Historical stock prices
Current Share PriceUS$34.50
52 Week HighUS$42.14
52 Week LowUS$7.45
Beta-0.28
1 Month Change7.81%
3 Month Change48.77%
1 Year Change283.33%
3 Year Change98.28%
5 Year Change-84.99%
Change since IPO-90.87%

Recent News & Updates

Seeking Alpha • Sep 18

Faeth Therapeutics: 'Buy' PIKTOR EC Data Year-End 2026 And HR+/HER2- BC Drug Expansion

Summary I am initiating Faeth Therapeutics with a "Buy" rating following its acquisition, name change, and $200M private placement. Company's lead asset, PIKTOR, targets multi-node PAM pathway alterations in endometrial cancer and HR+/HER2- breast cancer, with key phase 2 and 1b/2 data catalysts ahead. Topline results for PIKTOR in 2nd-line advanced endometrial cancer are expected by year-end 2026, with interim breast cancer data in 2027. Company's cash runway is sufficient for near-term catalysts, but increased trial expenses suggest a likely need for additional funding within several months. Read the full article on Seeking Alpha

Recent updates

Seeking Alpha • Sep 18

Faeth Therapeutics: 'Buy' PIKTOR EC Data Year-End 2026 And HR+/HER2- BC Drug Expansion

Summary I am initiating Faeth Therapeutics with a "Buy" rating following its acquisition, name change, and $200M private placement. Company's lead asset, PIKTOR, targets multi-node PAM pathway alterations in endometrial cancer and HR+/HER2- breast cancer, with key phase 2 and 1b/2 data catalysts ahead. Topline results for PIKTOR in 2nd-line advanced endometrial cancer are expected by year-end 2026, with interim breast cancer data in 2027. Company's cash runway is sufficient for near-term catalysts, but increased trial expenses suggest a likely need for additional funding within several months. Read the full article on Seeking Alpha
Analysis Article • Nov 03

Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Jul 02

We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Mar 14

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Aug 14

We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Aug 09

Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06

Sensei Biotherapeutics press release (NASDAQ:SNSE): Q2 GAAP EPS of -$0.34 beats by $0.06. Cash, cash equivalents and marketable securities were $123.7 million as of June 30, 2022, as compared to $147.6 million as of December 31, 2021. Sensei expects its current cash balance to fund operations into the first quarter of 2025.
Analysis Article • Apr 18

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Nov 16

Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

FTHUS BiotechsUS Market
7D-7.9%0.6%-0.2%
1Y283.3%36.5%12.1%

Return vs Industry: FTH exceeded the US Biotechs industry which returned 36.5% over the past year.

Return vs Market: FTH exceeded the US Market which returned 12.1% over the past year.

Price Volatility

Is FTH's price volatile compared to industry and market?
FTH volatility
FTH Average Weekly Movement16.1%
Biotechs Industry Average Movement9.5%
Market Average Movement6.8%
10% most volatile stocks in US Market15.1%
10% least volatile stocks in US Market2.9%

Stable Share Price: FTH's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: FTH's weekly volatility has decreased from 32% to 16% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199929Anand Parikhwww.faeththerapeutics.com

Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors.

Faeth Therapeutics, Inc. Fundamentals Summary

How do Faeth Therapeutics's earnings and revenue compare to its market cap?
FTH fundamental statistics
Market capUS$891.49m
Earnings (TTM)-US$195.53m
Revenue (TTM)n/a
0.0x
P/S Ratio
-4.6x
P/E Ratio

Is FTH overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
FTH income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$195.53m
Earnings-US$195.53m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-7.57
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did FTH perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/20 06:16
End of Day Share Price 2026/09/18 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Faeth Therapeutics, Inc. is covered by 19 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Zhiqiang ShuBerenberg
Suranjit MukherjeeBTIG